Guardant Health Stock Price, News & Analysis

Guardant Health, Inc. (NASDAQ: GH) announced that Palmetto GBA has granted coverage for its Guardant360 TissueNext™ test under the existing local coverage determination for next-generation sequencing of solid tumors. This tissue-based test aims to assist oncologists in identifying advanced cancer patients who may benefit from biomarker-informed treatments. Medicare will cover the test for fee-for-service patients with advanced solid tumor cancers. This marks an expansion of coverage for Guardant's tests and enhances access to genomic profiling for patients with advanced cancer.

Guardant Health reported strong Q4 2021 results with revenue of $108 million, a 38% increase year-over-year. For the full year, revenue reached $374 million, up 30%. Clinical tests surged by 48% to 25,600, while biopharma tests rose 36% to 6,600. Gross profit improved to $74.7 million with a 69% gross margin. Despite increased operating expenses of $172.9 million, the net loss narrowed to $90.9 million. The company expects 2022 revenue between $460 million and $470 million.

Guardant Health, a leading precision oncology company, will participate virtually in several key investor conferences in February and March 2022. The conferences include:

• 11th Annual SVB Leerink Global Healthcare Conference on February 16 at 9:00 a.m. PT.
• Citi 2022 Healthcare Conference on February 24 at 11:45 a.m. PT.
• Cowen 42nd Annual Health Care Conference on March 8 at 10:30 a.m. PT.

Live and archived webcasts will be available on the company's website. Guardant Health aims to enhance cancer care through its innovative tests and analytics.

Guardant Health, Inc. (NASDAQ: GH) announced it will release its financial results for Q4 and the full year 2021 on February 23, 2022, after market close. A conference call will follow at 1:30 p.m. PT (4:30 p.m. ET). The event can be streamed live from the company’s website, with an archive available post-event. Guardant Health specializes in precision oncology, offering advanced diagnostic tests like Guardant360 and Guardant Reveal to enhance cancer care.

Guardant Health (Nasdaq: GH) announced positive data from the interim analysis of the COSMOS-CRC-01 study, showcasing the Guardant Reveal™ liquid biopsy test's efficacy in detecting molecular residual disease in early-stage colorectal cancer. The test can identify disease recurrence with a lead time of over six months post-surgery. Additionally, the Guardant360® test demonstrated comparable detection rates for microsatellite instability-high status in advanced gastrointestinal cancers. These findings will be presented at the 2022 ASCO Gastrointestinal Cancers Symposium from January 20-22, 2022.

Guardant Health has initiated the SHIELD LUNG study, enrolling nearly 10,000 patients over 36 months to evaluate its blood test for detecting lung cancer in high-risk individuals aged 50-80. The study will take place across 100 centers in the U.S. and Europe. Lung cancer remains a leading cause of cancer-related deaths, with only 14% of eligible individuals adhering to current screening guidelines. Successful study outcomes could support a PMA submission to the FDA.

Guardant Health (GH) announced a settlement with Foundation Medicine regarding digital sequencing technology patents. Foundation Medicine will pay Guardant Health $25 million and future royalties. This agreement results in the dismissal of all pending patent litigation between the two companies. Guardant Health's Co-CEO, Helmy Eltoukhy, emphasized the significance of this settlement, highlighting the recognition of their scientific discoveries and strong intellectual property rights.

Guardant Health, a leader in precision oncology, announced its participation in the 40th Annual J.P. Morgan Healthcare Conference. The presentation will occur on January 10 at 12:00 p.m. PT / 3:00 p.m. ET. Investors can access the live and archived webcast through the company’s website. Guardant Health focuses on combating cancer using proprietary tests, including Guardant360® and Guardant Reveal™, aiming to improve outcomes and reduce healthcare costs across the cancer care continuum.

Guardant Health (NASDAQ: GH) announced it has reached a milestone in the ECLIPSE study, enrolling 12,750 patients to evaluate its LUNAR-2 blood test for colorectal cancer (CRC) detection. The study aims to support a PMA submission to the U.S. FDA, contingent on positive results. Colorectal cancer screening rates are currently low, and LUNAR-2 seeks to address this by providing a non-invasive blood test to improve access. This milestone reflects the commitment of researchers and participants during challenging times.